Britain and America have concluded a key bilateral deal that will guarantee no import taxes on British medicine shipments entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to increase spending on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these key products will remain at nothing for a timeframe of three years.
This agreement comes after recent warnings to significantly raise import taxes on patented pharmaceutical imports, with increases discussed reaching 100%.
"This agreement with the Britain reinforces the global environment for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. drug exports," a release said.
Trade Significance
Medicines are one of the the United Kingdom's largest goods shipped to the US, which is easily the primary market for major companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period leading up to September, the UK shipped medicines valued at billions to the US. This value accounted for 17.4% of all goods exports in that period.
"This deal safeguards employment, increases funding and paves the way for the UK to establish itself as a international leader for medical research," a government official remarked.
Detailed British Pledges
The agreement includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to double overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds were more than 20%.
Industry Background
The deal comes amid a protracted dispute between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
The disagreement were heightened by claims that American patients were paying several times more for the identical medicines than people in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been halted or cancelled, while major funding commitments have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to spend more on medicines, noting that its spending on drugs had shrunk as a proportion of its resources over the previous ten-year period.
